1Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
2Department of Neurology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Am J Trop Med Hyg. 2020 Aug;103(2):689-695. doi: 10.4269/ajtmh.20-0077. Epub 2020 May 21.
Patients with tuberculous meningitis (TBM) in any stage of the British Medical Research Council (BMRC) scale, if requiring mechanical ventilation (MV), are likely to have a poor outcome. We report the usefulness of BMRC, BMRC-MV, and BMRC-hydrocephalus (BMRC-HC) staging, and Haydarpasa Meningitis Severity Index (HAMSI) scoring in predicting the outcome of TBM. One hundred ninety-seven TBM patients were analyzed from a prospectively maintained TBM registry. The severity of meningitis was categorized using BMRC (stages I-III), BMRC-MV (I-IV [MV patients were grouped as stage IV]), and BMRC-HC (I-IV [BMRC stage III patients with hydrocephalus were grouped as stage IV]). Haydarpasa Meningitis Severity Index scoring was categorized as < 6 and ≥ 6. The outcome was defined at 6 months using the modified Rankin Scale (mRS) as death, poor (mRS score > 2), or good (mRS score ≤ 2). Forty-nine (25%) patients died. BMRC-mechanical ventilation stage IV had the highest predictive value for defining death, with a sensitivity of 88% and a specificity of 86%. About 81.7% of surviving patients had a good outcome at 6 months. BMRC-mechanical ventilation stages I-III had the highest predictive value for defining good outcome, with a sensitivity of 93% and a specificity of 61%. In TBM, BMRC-MV staging has the best predictive value for defining death and disability.
患有结核性脑膜炎(TBM)的患者,无论处于英国医学研究理事会(BMRC)分级的哪一阶段,如果需要机械通气(MV),其预后可能较差。我们报告了 BMRC、BMRC-MV 和 BMRC-脑积水(BMRC-HC)分期以及 Haydarpasa 脑膜炎严重程度指数(HAMSI)评分在预测 TBM 预后中的作用。从一个前瞻性的 TBM 登记处分析了 197 名 TBM 患者。使用 BMRC(I-III 期)、BMRC-MV(I-IV [MV 患者分为 IV 期])和 BMRC-HC(I-IV [BMRC 第 III 期伴有脑积水的患者分为 IV 期])对脑膜炎的严重程度进行分类。Haydarpasa 脑膜炎严重程度指数评分分为 < 6 和 ≥ 6。采用改良 Rankin 量表(mRS)在 6 个月时定义预后,死亡定义为 mRS 评分> 2,预后不良(mRS 评分> 2)或预后良好(mRS 评分≤ 2)。49 名(25%)患者死亡。BMRC-MV 分期 IV 期对死亡的预测价值最高,敏感性为 88%,特异性为 86%。大约 81.7%的存活患者在 6 个月时预后良好。BMRC-MV 分期 I-III 期对预后良好的预测价值最高,敏感性为 93%,特异性为 61%。在 TBM 中,BMRC-MV 分期对死亡和残疾的预测价值最高。